The country of origin of Valsartan and Hydrochlorothiazide Tablets USP, in dosage form
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Key passages, quoted from the ruling
- Therefore, we find the mixing of the active ingredients, Valsartan and Hydrochlorothiazide with the inactive ingredients into the final dosage tablets in India results in a substantial transformation and the country of origin will be India.
Ruling text
In your letter dated August 18, 2026, you requested a country of origin ruling on Valsartan and Hydrochlorothiazide Tablets USP, in dosage form. Valsartan and Hydrochlorothiazide, imported in various dosages in tablet form, is a medicinal preparation containing Valsartan (an angiotensin II receptor blocker) and Hydrochlorothiazide (a thiazide diuretic), as the active ingredients. It is indicated for the treatment of hypertension to lower blood pressure.
You stated that the active pharmaceutical ingredients (APIs), Valsartan and Hydrochlorothiazide, are manufactured in China and India, respectively. In India, these two APIs will be mixed with various inactive ingredients to produce the final Valsartan and Hydrochlorothiazide Tablets in dosage form. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).
In determining whether a substantial transformation occurs in the manufacture of chemical products such as pharmaceuticals, CBP has consistently examined the complexity of the processing and whether the final article retains the essential identity and character of the raw material. To that end, CBP has generally held that the processing of pharmaceutical products from bulk form into measured doses does not result in a substantial transformation of the product.
See, e.g., Headquarters Ruling (“HQ”) 561975, dated April 3, 2002; HQ 561544, dated May 1, 2000; HQ 735146, dated November 15, 1993; HQ H267177, dated November 5, 2016; HQ H233356, dated December 26, 2012; and, HQ 561975, dated April 3, 2002. However, where the processing from bulk form into measured doses involves the combination of two or more APIs, and the resulting combination offers additional medicinal benefits compared to taking each API alone, CBP has held that a substantial transformation occurred.
See, e.g., HQ 563207, dated June 1, 2005. In this case, we note that the two separate APIs are mixed to create a combination drug that offers additional medicinal benefits compared to taking each API alone. Therefore, we find the mixing of the active ingredients, Valsartan and Hydrochlorothiazide with the inactive ingredients into the final dosage tablets in India results in a substantial transformation and the country of origin will be India.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N364380).